![](/img/cover-not-exists.png)
PDB42 INCRETIN-THERAPY IN ADDITION TO METFORMIN AND/OR SULFONYLUREA FOR TYPE 2 DIABETES MELLITUS (T2DM): COSTEFFECTIVENESS OF LIRAGLUTIDE VERSUS EXENATIDE FROM THE PERSPECTIVE OF THE GERMAN STATUTORY HEALTH INSURANCE (SHI)
M Schlander, S Mentrup, N LundVolume:
13
Year:
2010
Language:
english
DOI:
10.1016/s1098-3015(11)72100-3
File:
PDF, 71 KB
english, 2010